Carl Zeiss Meditec AG (ADR)
General ticker "CZMWY" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $5.1B (TTM average)
Carl Zeiss Meditec AG (ADR) does not follow the US Stock Market performance with the rate: -15.8%.
Estimated limits based on current volatility of 1.3%: low 26.72$, high 27.47$
Factors to consider:
- Company pays dividends (annually): last record date 2025-03-28, amount 0.65$ (Y2.38%)
- Current price 33.2% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-09-30 to 2026-09-30
- 2024-09-30 to 2025-09-30 estimated range: [41.73$, 85.13$]
- 2025-09-30 to 2026-09-30 estimated range: [40.90$, 81.91$]
Financial Metrics affecting the CZMWY estimates:
- Negative: with PPE of 32.0 at the end of fiscal year the price was high
- Positive: -4.75 < Operating profit margin, % of 5.87
- Positive: Inventory ratio change, % of 0.69 <= 0.80
- Negative: Operating cash flow per share per price, % of 4.46 <= 6.64
- Negative: 42.68 < Shareholder equity ratio, % of 60.17 <= 64.29
- Positive: -14.22 < Investing cash flow per share per price, % of -7.44
- Positive: -9.07 < Industry operating profit margin (median), % of -7.25
Short-term CZMWY quotes
Long-term CZMWY plot with estimates
Financial data
| YTD | 2023-09-30 | 2024-09-30 |
|---|---|---|
| Operating Revenue | €2,089.30MM | €2,066.13MM |
| Operating Expenses | €1,762.16MM | €1,944.78MM |
| Operating Income | €327.14MM | €121.35MM |
| Non-Operating Income | €85.43MM | €119.52MM |
| Interest Expense | €1.92MM | €31.89MM |
| R&D Expense | €349.28MM | €343.09MM |
| Income(Loss) | €412.56MM | €240.87MM |
| Taxes | €120.56MM | €60.71MM |
| Profit(Loss)* | €290.40MM | €178.73MM |
| Stockholders Equity | €2,159.45MM | €2,041.70MM |
| Inventory | €519.62MM | €536.16MM |
| Assets | €3,032.92MM | €3,393.20MM |
| Operating Cash Flow | €250.86MM | €247.32MM |
| Capital expenditure | €113.86MM | €152.20MM |
| Investing Cash Flow | €-110.98MM | €-412.31MM |
| Financing Cash Flow | €-135.09MM | €176.25MM |
| Earnings Per Share** | €3.25 | €2.01 |
| Ordinary share to ADR | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.